


6355271







Managam of

Figure 1A
Therapeutic Calcium Phosphate
Particles and Methods of Manufacture And Use Steve J. D. Bell
USSN 09/496,771







Figure 1B












Figure 2










Figure 3



4A







Figure 4







FIGURE 5
Therapeutic Calcium Phosphate
Particles and Methods of Manufacture And Use Steve J. D. Bell
USSN 09/496,771






Figure 6

HSV-2 ELISA IgG
Ag conc. 6.25 µg/ml

OST 2.5

OST 1.5

OST 2.5

ACCURATE CAP


ACCURATE CAP

ACCURATE CAP

ACCURATE CAP

ACCURATE CAP

Weeks after primary immunization








FIGURE 7



EBV ELISA IgG2a Ag conc. 6.25 ug/ml 8B Absorbance Value (490nm) Ab dilution 1:800 0.4 0.3 0.2 CAP+EBV -EBV ALUM+EBV -CAP 0.1 2 10 12 Weeks post primary injection



EBV ELISA IgE Ag conc. 6.25 ug/ml 0.3 -CAPHEBY 0.2 -EBV ALUM+EBY 0.1 -CAP 0 10 12 Weeks post primary injection

FIGURE 8


Therapeutic Calcium Phosphate Particles and Methods of Manufacture And Use Steve J. D. Bell USSN 09/496,771

8C


8D

Figure 9







9B



9C





9D




Particles and Methods of Manufacture And Use Steve J. D. Bell USSN 09/496,771

Figure 10















Figure 11














Figure 15